KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Share-based Compensation (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Share-based Compensation for 17 consecutive years, with $46.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 9.64% year-over-year to $46.9 million, compared with a TTM value of $181.4 million through Dec 2025, down 10.0%, and an annual FY2025 reading of $181.4 million, down 10.0% over the prior year.
  • Share-based Compensation was $46.9 million for Q4 2025 at Biomarin Pharmaceutical, down from $49.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $58.2 million in Q1 2024 and bottomed at $37.7 million in Q1 2025.
  • Average Share-based Compensation over 5 years is $49.2 million, with a median of $48.7 million recorded in 2021.
  • The sharpest move saw Share-based Compensation increased 21.98% in 2021, then plummeted 35.28% in 2025.
  • Year by year, Share-based Compensation stood at $43.9 million in 2021, then grew by 6.48% to $46.7 million in 2022, then increased by 17.38% to $54.9 million in 2023, then dropped by 5.35% to $51.9 million in 2024, then decreased by 9.64% to $46.9 million in 2025.
  • Business Quant data shows Share-based Compensation for BMRN at $46.9 million in Q4 2025, $49.3 million in Q3 2025, and $47.5 million in Q2 2025.